Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel monoclonal antibodies for the treatment and diagnosis of cancer. The company is pursuing multiple company and investigator-sponsored clinical programs with its lead immunotherapy candidate bavituximab including the SUNRISE Phase III trial in patients with second-line non-small cell lung cancer. Other indications include front-line non-small cell lung, liver, breast and rectal cancers as well as melanoma. The company is also investigating an imaging agent that represents a potential new approach to imaging cancer. Peregrine has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com) which provides development and biomanufacturing services for both Peregrine and outside customers.
Company Growth (employees)
Type
Public
HQ
Tustin, US
Founded
1981
Size (employees)
319 (est)+14%
Peregrine Pharmaceuticals was founded in 1981 and is headquartered in Tustin, US

Peregrine Pharmaceuticals Office Locations

Peregrine Pharmaceuticals has an office in Tustin
Tustin, US (HQ)
14282 Franklin Ave

Peregrine Pharmaceuticals Financials and Metrics

Peregrine Pharmaceuticals Financials

Peregrine Pharmaceuticals's revenue was reported to be $44.7 m in FY, 2016
USD

Net income (Q1, 2018)

(1.2 m)

EBIT (Q1, 2018)

(1.2 m)

Market capitalization (13-Nov-2017)

199.2 m

Cash (31-Jul-2017)

37.3 m
Peregrine Pharmaceuticals's current market capitalization is $199.2 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

22.4 m26.8 m44.7 m

Revenue growth, %

20%67%

R&D expense

59.5 m

General and administrative expense

18.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

7.4 m3.9 m5.5 m6.3 m5.7 m9.7 m9.5 m6.7 m5.6 m23.4 m10.7 m

R&D expense

7 m6.6 m10.2 m10 m11.3 m13.9 m14.2 m15.2 m8.6 m7 m6 m3.6 m

General and administrative expense

4 m4.6 m4.9 m4.3 m4.3 m4.9 m4.4 m4.5 m5.1 m5 m4.6 m4.2 m

Operating expense total

15.2 m13.6 m18.7 m18.4 m18.7 m23.4 m23.3 m23.6 m16.7 m27.4 m18.5 m28.3 m
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

77.5 m68 m61.4 m

Inventories

5.5 m7.4 m16.2 m33.1 m

Current Assets

85.8 m80.5 m81.8 m

PP&E

2.4 m15.1 m24.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

44.4 m63.2 m55.2 m59 m72 m67.5 m44.2 m49.1 m41.5 m37.3 m

Inventories

4 m5.2 m6.1 m10.5 m12.6 m15.2 m25.3 m25.9 m33.8 m24.2 m

Current Assets

51.3 m72.2 m68.6 m72.3 m89.5 m93.6 m78.2 m82.8 m83 m70.8 m

PP&E

2.3 m2.5 m9 m18.4 m21.8 m23.8 m24.3 m24 m24.1 m24.4 m
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(35.4 m)(50.4 m)(55.7 m)(28.2 m)

Depreciation and Amortization

986 k1 m1.5 m2.5 m

Inventories

(1.2 m)(1.8 m)(8.8 m)(16.9 m)

Accounts Payable

(391 k)3.3 m(3.5 m)(3.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(7.8 m)(9.7 m)(13.1 m)(25.2 m)(13 m)(13.7 m)(13.2 m)(16.8 m)(11.1 m)(4.1 m)(7.8 m)

Depreciation and Amortization

277 k542 k

Inventories

(468 k)151 k6.1 m10.5 m12.6 m15.2 m25.3 m25.9 m33.8 m

Accounts Payable

2.5 m484 k6.8 m9.8 m6.9 m7.8 m9.1 m11.6 m7.7 m
Y, 2017

Financial Leverage

1.8 x
Show all financial metrics

Peregrine Pharmaceuticals Operating Metrics

FY, 2016

Phase 1/2

1
Show all operating metrics

Peregrine Pharmaceuticals Market Value History

Peregrine Pharmaceuticals Revenue Breakdown

Peregrine Pharmaceuticals's Web-traffic and Trends

Peregrine Pharmaceuticals Company Life and Culture

You may also be interested in